|Bid||0.89 x 1200|
|Ask||0.94 x 800|
|Day's Range||0.9200 - 0.9410|
|52 Week Range||0.5100 - 2.3000|
|Beta (3Y Monthly)||3.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.75|
NEW YORK, NY / ACCESSWIRE / February 14, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire StateBuilding in New ...
Asterias Biotherapeutics (AST) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided top-line 12 month data from the Company’s Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of OPC1 in the treatment of severe cervical spinal cord injury (SCI). All 25 subjects from the SCiStar study have now completed 12-months of follow-up as part of the study’s protocol. The Company also held a Type B meeting with the Food and Drug Administration (FDA) late last year where FDA agreed with the Company’s plan to initiate a randomized, controlled Phase 2 study to further evaluate the safety and efficacy of OPC1.
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts, M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective January 7, 2019. "I’m excited to welcome Brandi to the BioTime team during this critical period in which we increase the focus on our clinical-stage product candidates and improve our business structure through recently-announced and pending transactions involving our affiliated companies, AgeX (NYSE American: AGE) and Asterias (NYSE American: AST),” stated Brian M. Culley, Chief Executive Officer of BioTime.
Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.
Asterias Biotherapeutics (AST) delivered earnings and revenue surprises of 20.00% and 10.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Fremont, California-based company said it had a loss of 8 cents per share. The stem cell therapy developer posted revenue of $116,000 in the period. In the final minutes of trading on Friday, the company's ...
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Asterias Biotherapeutics, Inc. ...
NEW YORK , Nov. 8, 2018 /PRNewswire/ -- Wolf Popper LLP is investigating claims on behalf of investors in Asterias Biotherapeutics, Inc. (NYSE American: AST) concerning the proposed acquisition of Asterias ...
BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc. (“Asterias”) (NYSE American: AST), today announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Asterias that are not currently owned by BioTime. Asterias stockholders will receive 0.71 shares of BioTime common shares for every share of Asterias common stock and will own approximately 16.2% of the combined company.
ALAMEDA, Calif.-- -- Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence Ltd. Positive OpRegen® Data Presented at 2018 American Academy of Ophthalmology Annual Meeting Date Set for Distribution of AgeX Therapeutics Shares to BioTime Stockholders BioTime, Inc. , a clinical-stage ...
Every investor in Asterias Biotherapeutics Inc (NYSEMKT:AST) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see Read More...
Asterias Biotherapeutics Inc (NYSEMKT:AST), a US$74.9m small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...
Investors in Asterias Biotherapeutics (AST) need to pay close attention to the stock based on moves in the options market lately.